Seventeen of the world’s largest branded drug manufacturers have been paying a 100 percent import tariff on their patented medicines and pharmaceutical ingredients since July 31, 2026. Every other pharmaceutical importer, meaning every company not named on that list, reaches the identical 100 percent rate on September 29, 2026, a date now nineteen days away. Both dates trace back to a single presidential proclamation signed five months ago, and the gap between them was not an administrative accident. It was built into the tariff from the start.
What Annex III Is and How a Company Lands On It
Proclamation 11020, issued April 2, 2026 under Section 232 of the Trade Expansion Act of 1962, found that pharmaceutical imports threaten to impair national security. The Commerce Department’s investigation determined that roughly 53 percent of patented pharmaceutical products distributed domestically are produced outside the United States, and that only 15 percent of patented active pharmaceutical ingredients by volume are made domestically. On that basis, the proclamation imposes a 100 percent ad valorem duty on the patented drugs and ingredients listed in its Annex I, then splits the calendar for when that duty actually applies by company: importers named in Annex III began paying it on July 31, 2026, and every other pharmaceutical importer starts paying it on September 29, 2026.
The published text of the proclamation in the Federal Register does not spell out, in searchable form, a formal size or volume threshold for Annex III membership; the annex itself is reproduced only as a scanned image in the official filing. What is verifiable is the effect, not a stated formula: trade and legal analyses examining the roster have reported that it names seventeen major branded manufacturers, and that at least thirteen of them had already reached company-specific tariff agreements or onshoring arrangements with the Commerce Department before the proclamation was even signed in April. The pattern that emerges is companies the government had already engaged on pricing or onshoring terms moved onto the accelerated date, while the rest of the industry did not.
Free retirement updates: Want plain-English help keeping more of your money in retirement? The free Retirement Shield newsletter covers the benefits, deadlines, and money mistakes that cost retirees, a couple times a week. Subscribe free.
A Named-Company Rollout Is Not How Section 232 Usually Works
Section 232 tariffs, the same statutory authority behind the 2018 steel and aluminum duties, typically apply uniformly to an entire product category by country of origin on a single effective date. This proclamation instead layered in two company-specific instruments alongside the tariff itself: Annex II, the list of companies with tariff agreements Commerce had already finalized before the proclamation, and Annex III, the list moved onto the accelerated July 31 date. Naming individual corporate importers for different start dates, rather than applying one date to the whole product category, is the unusual part of this particular Section 232 action.
The staggered timeline did not exempt everyone else from compliance work on July 31. Customs and Border Protection’s implementing guidance, CSMS #69395344, issued July 30, 2026, required every importer of the covered pharmaceutical tariff classifications, Annex III company or not, to begin reporting the new Chapter 99 codes on July 31, using a temporary zero-duty classification if the company was not on Annex III. That detail suggests the phase-in was less about giving the broader industry time to build reporting systems, since that obligation applied to everyone from day one, and more about which companies Commerce was prepared to actually bill first.
September 29 Is the Date the Tariff Leaves the Boardroom
For the first sixty days, the 100 percent tariff reached only a short list of household-name manufacturers with the deepest existing negotiating relationship with Commerce and the Department of Health and Human Services. A separate Commerce notice, published May 13, 2026 to establish the process for company-specific onshoring deals, describes September 29, 2026 as the date the tariff becomes effective for most companies, confirming the same date from an independent, later filing rather than only the original proclamation.
That expansion moves the tariff from a small roster of the largest branded manufacturers to the much broader population of pharmaceutical importers: smaller branded drugmakers, licensees, and contract importers who lacked the scale or leverage to negotiate an onshoring plan or a pricing agreement before the deadlines passed. This is the population whose costs are most likely to surface in pharmacy wholesale contracts and inventory pricing, because it has had far less runway to restructure a supply chain or qualify for a reduced rate. The window to apply for a Commerce-approved onshoring plan closed June 12, 2026, so an importer newly reaching the tariff on September 29 without an application already on file has no near-term path to the reduced 20 percent or zero percent rates.
Six Weeks In, No Agency Has Published a Price Effect
Six weeks have passed since the Annex III companies started paying the 100 percent rate, and no Customs and Border Protection guidance, Commerce Department notice, or other primary release found for this article isolates a price change attributable specifically to that phase. That absence is not proof costs disappeared; it is simply the current state of the public record. Drug-pricing researchers who commented when the tariff took effect largely expected the opposite of an immediate jump at the pharmacy counter. Yale-affiliated pricing researcher Melissa Barber said patented drugs are generally already priced at what the market will bear, leaving manufacturers little room to add the tariff on top of existing list prices in the short run. A securities-research estimate cited in that same reporting put the tariffs’ eventual industry-wide cost at roughly $46 billion against about $700 billion in annual revenue for the largest manufacturers, a gap analysts expected companies to absorb rather than pass through immediately. Whether that changes once the tariff reaches the wider importer population on September 29 has no published answer yet.
Generic Drugs, Biosimilars and Orphan Drugs Stay Outside This Tariff
The proclamation exempts generic pharmaceuticals and their associated ingredients, including biosimilar products, from Section 232 duties entirely, and sets a zero tariff rate for drugs where every approved indication carries an orphan designation, along with nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies, antibody-drug conjugates, and certain animal-health products meeting additional conditions. That distinction is the honest counterweight to the headline number for an older reader watching Medicare Part D or Medicare Advantage drug costs: most prescriptions filled by retirees are for generic medications, which this tariff does not touch regardless of which company imports them or on what date. The brand-name biologics that do carry the 100 percent duty, treatments for cancer, autoimmune disease, and other chronic conditions common among Medicare beneficiaries, are the ones more likely to sit on a formulary’s highest cost tier if any of this cost eventually moves into premiums or plan pricing.
CBP’s own guidance states the generic exemption without qualification: generic pharmaceuticals and their associated ingredients are not subject to the additional duties. That line, from the agency actually collecting the tariff at the border, is the plainest statement available of where September 29 will and will not reach.
This article was produced with the assistance of AI and reviewed by The Financial Wire editorial team.
More Financial Reading
- The ideal retirement withdrawal rate so your savings actually last
- Bank statements: how long to keep them and when to toss them
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
